Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 162 articles:
HTML format



Single Articles


    August 2022
  1. SHAH M, Osgood CL, Amatya AK, Fiero MH, et al
    FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple Negative Breast Cancer.
    Clin Cancer Res. 2022 Aug 4. pii: 707438. doi: 10.1158/1078-0432.CCR-22-1110.
    PubMed     Abstract available


  2. SINGER CF, Holst F, Steurer S, Burandt EC, et al
    Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
    Clin Cancer Res. 2022 Aug 3:OF1-OF9. doi: 10.1158/1078-0432.CCR-21-4328.
    PubMed     Abstract available


    July 2022
  3. SUN K, Xu Y, Zhang L, Niravath P, et al
    A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2022 Jul 25. pii: 707209. doi: 10.1158/1078-0432.CCR-22-0622.
    PubMed     Abstract available


  4. GLUZ O, Nitz U, Kolberg-Liedtke C, Prat A, et al
    De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial.
    Clin Cancer Res. 2022 Jul 7. pii: 706903. doi: 10.1158/1078-0432.CCR-22-0482.
    PubMed     Abstract available


  5. SALGADO R, Loi S
    What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet.
    Clin Cancer Res. 2022;28:2728-2729.
    PubMed     Abstract available


    June 2022
  6. ZHANG J, Ji D, Shen W, Xiao Q, et al
    Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2022 Jun 29:OF1-OF10. doi: 10.1158/1078-0432.CCR-22-0456.
    PubMed     Abstract available


  7. KUMAR T, Hobbs E, Yang F, Chang JT, et al
    Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation.
    Clin Cancer Res. 2022 Jun 23. pii: 705099. doi: 10.1158/1078-0432.CCR-21-1278.
    PubMed     Abstract available


  8. LI J, Jiang J, Bao X, Kumar V, et al
    Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases.
    Clin Cancer Res. 2022 Jun 21:OF1-OF13. doi: 10.1158/1078-0432.CCR-22-0405.
    PubMed     Abstract available


  9. YIN W, Wang Y, Wu Z, Ye Y, et al
    Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
    Clin Cancer Res. 2022 Jun 17. pii: 704938. doi: 10.1158/1078-0432.CCR-22-0446.
    PubMed     Abstract available


  10. XIA Y, He X, Renshaw L, Martinez-Perez C, et al
    Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer.
    Clin Cancer Res. 2022 Jun 2. pii: 699314. doi: 10.1158/1078-0432.CCR-21-3189.
    PubMed     Abstract available


  11. FASCHING PA, Liu D, Scully S, Ingle JN, et al
    Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Breast Cancer Patients.
    Clin Cancer Res. 2022 Jun 2. pii: 699313. doi: 10.1158/1078-0432.CCR-20-4774.
    PubMed     Abstract available


  12. SUMAN VJ, Du L, Hoskin T, Anurag M, et al
    Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031).
    Clin Cancer Res. 2022 Jun 2. pii: 699315. doi: 10.1158/1078-0432.CCR-22-0068.
    PubMed     Abstract available


  13. BYCHKOVSKY BL, Li T, Sotelo J, Tayob N, et al
    Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    Clin Cancer Res. 2022;28:2349-2360.
    PubMed     Abstract available


    May 2022
  14. ZHANG J, Ji D, Shen W, Xiao Q, et al
    Phase I Trial of a Novel Anti-HER2 Antibody-drug Conjugate, ARX788, for the Treatment of HER2-positive Metastatic Breast Cancer.
    Clin Cancer Res. 2022 May 26. pii: 699249. doi: 10.1158/1078-0432.CCR-22-0456.
    PubMed     Abstract available


  15. LINDEMAN GJ, Fernando TM, Bowen R, Jerzak KJ, et al
    VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, Biomarker Results.
    Clin Cancer Res. 2022 May 18. pii: 699022. doi: 10.1158/1078-0432.CCR-21-3811.
    PubMed     Abstract available


  16. BONI V, Fidler MJ, Arkenau HT, Spira A, et al
    Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
    Clin Cancer Res. 2022;28:2020-2029.
    PubMed     Abstract available


  17. DMELLO C, Sonabend A, Arrieta VA, Zhang DY, et al
    Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma.
    Clin Cancer Res. 2022 May 12. pii: 698878. doi: 10.1158/1078-0432.CCR-21-2563.
    PubMed     Abstract available


  18. RADOVICH M, Solzak JP, Wang CJ, Hancock BA, et al
    Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer.
    Clin Cancer Res. 2022 May 12. pii: 698879. doi: 10.1158/1078-0432.CCR-21-3078.
    PubMed     Abstract available


  19. COLEMAN IM, DeSarkar N, Morrissey C, Xin L, et al
    Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2022 May 12. pii: 698880. doi: 10.1158/1078-0432.CCR-21-4289.
    PubMed     Abstract available


  20. YAM C, Abuhadra N, Sun R, Adrada BE, et al
    Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer.
    Clin Cancer Res. 2022 May 4. pii: 696297. doi: 10.1158/1078-0432.CCR-21-3100.
    PubMed     Abstract available


    April 2022
  21. TOLANEY SM, Toi M, Neven P, Sohn J, et al
    Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
    Clin Cancer Res. 2022;28:1500-1506.
    PubMed     Abstract available


  22. BLENMAN KRM, Marczyk M, Karn T, Qing T, et al
    Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer.
    Clin Cancer Res. 2022 Apr 4. pii: 694190. doi: 10.1158/1078-0432.CCR-21-3215.
    PubMed     Abstract available


  23. LIM JSJ, Wong ALA, Ow SGW, Ngoi NYL, et al
    Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694118. doi: 10.1158/1078-0432.CCR-21-4179.
    PubMed     Abstract available


  24. WESTPHALEN CB, Fine AD, Andre F, Ganesan S, et al
    Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Clin Cancer Res. 2022;28:1412-1421.
    PubMed     Abstract available


    March 2022
  25. YEHIA L, Eng C
    One Size Does Not Fit All: Breast Cancer in Young Women.
    Clin Cancer Res. 2022 Mar 23. pii: 688107. doi: 10.1158/1078-0432.CCR-22-0352.
    PubMed     Abstract available


  26. BERGAMINO MA, Morani G, Parker J, Schuster EF, et al
    Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.
    Clin Cancer Res. 2022;28:1217-1228.
    PubMed     Abstract available


  27. VIGANO L, Locatelli A, Ulisse A, Galbardi B, et al
    Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer.
    Clin Cancer Res. 2022 Mar 7. pii: 682079. doi: 10.1158/1078-0432.CCR-21-3185.
    PubMed     Abstract available


  28. CHEN L, Jiang YZ, Wu SY, Wu J, et al
    Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial.
    Clin Cancer Res. 2022 Mar 3. pii: 681997. doi: 10.1158/1078-0432.CCR-21-4313.
    PubMed     Abstract available


    February 2022
  29. LENOUE-NEWTON ML, Chen SC, Stricker T, Hyman DM, et al
    Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE.
    Clin Cancer Res. 2022 Feb 18. pii: 681702. doi: 10.1158/1078-0432.CCR-21-0885.
    PubMed     Abstract available


  30. BUNDRED N, Porta N, Brunt AM, Cramer A, et al
    Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
    Clin Cancer Res. 2022 Feb 14. pii: 1078-0432.CCR-21-3177.
    PubMed     Abstract available


  31. BATALINI F, Xiong N, Tayob N, Polak M, et al
    Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
    Clin Cancer Res. 2022 Feb 11. pii: 1078-0432.CCR-21-3045.
    PubMed     Abstract available


  32. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
    Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study.
    Clin Cancer Res. 2022 Feb 10. pii: 1078-0432.CCR-21-3385.
    PubMed     Abstract available


  33. KURANI H, Razavipour SF, Harikumar KB, Dunworth M, et al
    DOT1L is a novel cancer stem cell target for triple negative breast cancer.
    Clin Cancer Res. 2022 Feb 8. pii: 1078-0432.CCR-21-1299.
    PubMed     Abstract available


  34. PEDDI PF, Fasching PA, Liu D, Quinaux E, et al
    Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.
    Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-1762.
    PubMed     Abstract available


    January 2022
  35. WAKS AG, Kim D, Jain E, Snow C, et al
    Somatic and germline genomic alterations in very young women with breast cancer.
    Clin Cancer Res. 2022 Jan 31. pii: 1078-0432.CCR-21-2572.
    PubMed     Abstract available


  36. BLUM JL, Laird AD, Litton JK, Rugo HS, et al
    Determinants of Response to Talazoparib in Patients with HER2-negative, Germline BRCA1/2-mutated Breast Cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-2080.
    PubMed     Abstract available


  37. MA CX, Luo J, Freedman RA, Pluard TJ, et al
    The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3418.
    PubMed     Abstract available


  38. SCHWARTZ CJ, da Silva EM, Marra A, Gazzo AM, et al
    Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
    Clin Cancer Res. 2022;28:404-413.
    PubMed     Abstract available


  39. GARCIA-SAENZ JA, Martinez-Janez N, Cubedo R, Jerez Y, et al
    Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor.
    Clin Cancer Res. 2022 Jan 3. pii: 1078-0432.CCR-21-2652.
    PubMed     Abstract available


    December 2021
  40. KESTER L, Seinstra D, van Rossum AGJ, Vennin C, et al
    Differential survival and therapy benefit of breast cancer patients are characterized by distinct epithelial and immune cell microenvironments.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1442.
    PubMed     Abstract available


  41. LU YS, Im SA, Colleoni M, Franke F, et al
    Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-3032.
    PubMed     Abstract available


  42. FITZPATRICK A, Iravani M, Mills A, Childs L, et al
    Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3017.
    PubMed     Abstract available


  43. ROYCE M, Osgood CL, Amatya AK, Fiero MH, et al
    FDA Approval Summary: Margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer.
    Clin Cancer Res. 2021 Dec 16. pii: 1078-0432.CCR-21-3247.
    PubMed     Abstract available


  44. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
    Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
    Clin Cancer Res. 2021;27:6815-6823.
    PubMed     Abstract available


  45. SHI Z, Wulfkuhle J, Nowicka M, Gallagher RI, et al
    Functional Mapping of AKT Signaling and Biomarkers of Response From the FAIRLANE Trial of Neoadjuvant Ipatasertib Plus Paclitaxel for Triple-Negative Breast Cancer.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-2498.
    PubMed     Abstract available


  46. TAN AR, Wright GS, Thummala AR, Danso MA, et al
    Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study.
    Clin Cancer Res. 2021 Dec 9. pii: 1078-0432.CCR-21-2272.
    PubMed     Abstract available


  47. ZHOU Q, Gampenrieder SP, Frantal S, Rinnerthaler G, et al
    Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response.
    Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-3231.
    PubMed     Abstract available


  48. ATRAFI F, Boix O, Subbiah V, Diamond JR, et al
    A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
    Clin Cancer Res. 2021;27:6366-6375.
    PubMed     Abstract available


    November 2021
  49. MOORE HCF, Barlow WE, Somlo G, Gralow JR, et al
    A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3131.
    PubMed     Abstract available


  50. ZHANG J, Ji D, Cai L, Yao H, et al
    First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-2827.
    PubMed     Abstract available


  51. HUA X, Bi XW, Zhao JL, Shi YX, et al
    Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002).
    Clin Cancer Res. 2021 Nov 22. pii: 1078-0432.CCR-21-3435.
    PubMed     Abstract available


  52. NIE P, Kalidindi T, Nagle VL, Wu X, et al
    Imaging of Cancer gamma-Secretase Activity Using an Inhibitor-Based PET Probe.
    Clin Cancer Res. 2021;27:6145-6155.
    PubMed     Abstract available


  53. LLOYD MR, Spring LM, Bardia A, Wander SA, et al
    Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities.
    Clin Cancer Res. 2021 Nov 1. pii: 1078-0432.CCR-21-2947.
    PubMed     Abstract available


  54. SARDESAI SD, Thomas A, Gallagher C, Lynce F, et al
    Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.
    Clin Cancer Res. 2021;27:5810-5817.
    PubMed     Abstract available


    October 2021
  55. ADAMS S, Othus M, Patel SP, Miller KD, et al
    A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
    Clin Cancer Res. 2021 Oct 29. pii: 1078-0432.CCR-21-2182.
    PubMed     Abstract available


  56. ARORA S, Narayan P, Osgood CL, Wedam S, et al
    U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
    Clin Cancer Res. 2021 Oct 28. pii: 1078-0432.CCR-21-2600.
    PubMed     Abstract available


  57. DIECI MV, Guarneri V, Tosi A, Bisagni G, et al
    Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2260.
    PubMed     Abstract available


  58. SYMMANS WF
    Interpreting the Complex Landscape of Immune-Tumor Interface.
    Clin Cancer Res. 2021;27:5446-5448.
    PubMed     Abstract available


  59. VENET D, Rediti M, Maetens M, Fumagalli D, et al
    Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
    Clin Cancer Res. 2021;27:5607-5618.
    PubMed     Abstract available


  60. ELKHOLI IE, Foulkes WD, Rivera B
    MRN Complex and Cancer Risk: Old Bottles, New Wine.
    Clin Cancer Res. 2021;27:5465-5471.
    PubMed     Abstract available


  61. DOWSETT M, Kilburn L, Rimawi MF, Osborne CK, et al
    Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1628.
    PubMed     Abstract available


  62. ASLEH K, Tu D, Gao D, Bramwell V, et al
    Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials.
    Clin Cancer Res. 2021 Oct 6. pii: 1078-0432.CCR-21-1942.
    PubMed     Abstract available


  63. KUEMMEL S, Campone M, Loirat D, Lopez Lopez R, et al
    A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer.
    Clin Cancer Res. 2021 Oct 6. pii: 1078-0432.CCR-20-3955.
    PubMed     Abstract available


  64. THORAT MA, Levey PM, Jones JL, Pinder SE, et al
    Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.
    Clin Cancer Res. 2021;27:5317-5324.
    PubMed     Abstract available


    September 2021
  65. SANCHEZ-GUIXE M, Hierro C, Jimenez J, Viaplana C, et al
    High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1810.
    PubMed     Abstract available


  66. SCHOUTEN PC, Richters LK, Vis DJ, Kommoss S, et al
    Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1673.
    PubMed     Abstract available


  67. PIZZAMIGLIO S, Ciniselli CM, Triulzi T, Gargiuli C, et al
    Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis.
    Clin Cancer Res. 2021 Sep 21. pii: 1078-0432.CCR-21-1600.
    PubMed     Abstract available


  68. MARQUEZ-ORTIZ RA, Contreras-Zarate MJ, Tesic V, Alvarez-Eraso KL, et al
    IL13Ralpha2 promotes proliferation and outgrowth of breast cancer brain metastases.
    Clin Cancer Res. 2021 Sep 20. pii: 1078-0432.CCR-21-0361.
    PubMed     Abstract available


  69. PUHALLA SL, Dieras V, Arun BK, Kaufman B, et al
    Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
    Clin Cancer Res. 2021;27:4983-4993.
    PubMed     Abstract available


  70. PAOLETTI C, Barlow WE, Cobain EF, Bergqvist M, et al
    Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial.
    Clin Cancer Res. 2021 Sep 14. pii: 1078-0432.CCR-21-1562.
    PubMed     Abstract available


  71. WESTIN SN, Labrie M, Litton JK, Blucher A, et al
    Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-1656.
    PubMed     Abstract available


  72. DE ANGELIS C, Fu X, Cataldo ML, Nardone A, et al
    Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
    Clin Cancer Res. 2021;27:4939.
    PubMed    


    August 2021
  73. VATHIOTIS IA, Moutafi MK, Divakar P, Aung TN, et al
    Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer.
    Clin Cancer Res. 2021 Aug 31. pii: 1078-0432.CCR-21-2103.
    PubMed     Abstract available


  74. JHAVERI K, Juric D, Yap YS, Cresta S, et al
    A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
    Clin Cancer Res. 2021 Aug 25. pii: 1078-0432.CCR-21-1095.
    PubMed     Abstract available


  75. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    PubMed     Abstract available


  76. GUARDIA C, Bianchini G, Arpi-LLucia O, Menendez S, et al
    Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
    Clin Cancer Res. 2021 Aug 12. pii: 1078-0432.CCR-20-2915.
    PubMed     Abstract available


  77. FILIPITS M, Rudas M, Kainz V, Singer CF, et al
    The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early-stage breast cancer: A validation study in ABCSG Trial 8.
    Clin Cancer Res. 2021 Aug 11. pii: 1078-0432.CCR-21-1023.
    PubMed     Abstract available


  78. SAURA C, Matito J, Oliveira M, Wildiers H, et al
    Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine vs Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
    Clin Cancer Res. 2021 Aug 11. pii: 1078-0432.CCR-21-1584.
    PubMed     Abstract available


  79. NEVEN P, Johnston SRD, Toi M, Sohn J, et al
    MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer.
    Clin Cancer Res. 2021 Aug 10. pii: 1078-0432.CCR-20-4685.
    PubMed     Abstract available


  80. NUNES R, Sella T, Treuner K, Atkinson JM, et al
    Prognostic utility of Breast Cancer Index to stratify distant recurrence risk in invasive lobular carcinoma.
    Clin Cancer Res. 2021 Aug 10. pii: 1078-0432.CCR-21-0733.
    PubMed     Abstract available


    July 2021
  81. GONZALEZ-ERICSSON PI, Wulfkhule JD, Gallagher RI, Sun X, et al
    Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer.
    Clin Cancer Res. 2021 Jul 27. pii: 1078-0432.CCR-21-0607.
    PubMed     Abstract available


  82. TURNER NC, Balmana J, Poncet C, Goulioti T, et al
    Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-0310.
    PubMed     Abstract available


  83. BLEACH R, Madden SF, Hawley J, Charmsaz S, et al
    Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy.
    Clin Cancer Res. 2021;27:3980-3989.
    PubMed     Abstract available


  84. YAM C, Yen EY, Chang JT, Bassett RL, et al
    Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2021 Jul 12. pii: 1078-0432.CCR-21-0144.
    PubMed     Abstract available


  85. DECENSI A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, et al
    Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease.
    Clin Cancer Res. 2021;27:3576-3583.
    PubMed     Abstract available


    June 2021
  86. KOH SB, Ross K, Isakoff SJ, Melkonjan N, et al
    RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-0714.
    PubMed     Abstract available


  87. STRELL C, Folkvaljon D, Holmberg E, Schiza A, et al
    High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial.
    Clin Cancer Res. 2021;27:3469-3477.
    PubMed     Abstract available


  88. HE X, Ji J, Dai X, Qdaisat AZ, et al
    Association of cardiovascular disease risk factors with late cardiotoxicity and survival in HER2-positive breast cancer survivors.
    Clin Cancer Res. 2021 Jun 11. pii: 1078-0432.CCR-20-4162.
    PubMed     Abstract available


  89. ANWAR M, Chen Q, Ouyang D, Wang S, et al
    Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0474.
    PubMed     Abstract available


  90. THOMPSON PA, Huang C, Yang J, Wertheim BC, et al
    Sulindac, a non-selective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0732.
    PubMed     Abstract available


  91. POTTER DA, Thomas A, Rugo HS
    A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-1133.
    PubMed     Abstract available


  92. CARTER JM, Polley MC, Leon-Ferre RA, Sinnwell J, et al
    Characteristics and spatially-defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0343.
    PubMed     Abstract available


  93. BAI Y, Cole K, Martinez-Morilla S, Ahmed FS, et al
    An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0325.
    PubMed     Abstract available


  94. WU AML, Gossa S, Samala R, Chung MA, et al
    Aging and CNS myeloid cell depletion attenuate breast cancer brain metastasis.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1549.
    PubMed     Abstract available


  95. BOUGHEY JC, Suman VJ, Yu J, Santo K, et al
    Patient Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).
    Clin Cancer Res. 2021 Jun 2. pii: 1078-0432.CCR-21-0641.
    PubMed     Abstract available


  96. COMPTE M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, et al
    An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
    Clin Cancer Res. 2021;27:3167-3177.
    PubMed     Abstract available


    May 2021
  97. SERVETTO A, Kollipara R, Formisano L, Lin CC, et al
    Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER+ breast cancer.
    Clin Cancer Res. 2021 May 19. pii: 1078-0432.CCR-20-3905.
    PubMed     Abstract available


  98. THORAT MA, Levey PM, Jones JL, Pinder SE, et al
    Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial.
    Clin Cancer Res. 2021;27:2861-2867.
    PubMed     Abstract available


  99. JHAVERI K, Drago JZ, Shah PD, Wang R, et al
    A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-21-0047.
    PubMed     Abstract available


  100. TELLI ML, Nagata H, Wapnir I, Acharya CR, et al
    Intratumoral Plasmid IL12 Expands CD8(+) T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.
    Clin Cancer Res. 2021;27:2481-2493.
    PubMed     Abstract available


    April 2021
  101. RUGO HS, Huppert L
    Answers are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer.
    Clin Cancer Res. 2021 Apr 9. pii: 1078-0432.CCR-21-0353.
    PubMed     Abstract available


  102. LIM B, Potter DA, Salkeni MA, Silverman P, et al
    Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4131.
    PubMed     Abstract available


  103. HONG DS, Moore KN, Bendell JC, Karp DD, et al
    Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
    Clin Cancer Res. 2021;27:1864-1874.
    PubMed     Abstract available


  104. CLAUSER P, Krug B, Bickel H, Dietzel M, et al
    Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy.
    Clin Cancer Res. 2021;27:1941-1948.
    PubMed     Abstract available


    March 2021
  105. VERNIERI C, Nichetti F, Lalli L, Moscetti L, et al
    Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET).
    Clin Cancer Res. 2021 Mar 30. pii: 1078-0432.CCR-20-4928.
    PubMed     Abstract available


  106. AKCAKANAT A, Zheng X, Cruz Pico CX, Kim T, et al
    Genomic, Transcriptomic and Proteomic Profiling of Metastatic Breast Cancer.
    Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-4048.
    PubMed     Abstract available


  107. NARAYAN P, Osgood CL, Singh H, Chiu HJ, et al
    FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4557.
    PubMed     Abstract available


  108. LI CI, Zhang Y, Cieslik M, Wu YM, et al
    Cancer cell-intrinsic and immunological phenotypes determine clinical outcomes in basal-like breast cancer.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-3890.
    PubMed     Abstract available


  109. TOLANEY SM, Kalinsky K, Kaklamani V, D'Adamo DR, et al
    Eribulin Plus Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase 1b/2 Study.
    Clin Cancer Res. 2021 Mar 16. pii: 1078-0432.CCR-20-4726.
    PubMed     Abstract available


  110. BARDIA A, Hurvitz SA, DeMichele A, Clark AS, et al
    Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1).
    Clin Cancer Res. 2021 Mar 15. pii: 1078-0432.CCR-20-2114.
    PubMed     Abstract available


  111. ZHAO M, Scott S, Evans KW, Yuca E, et al
    Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Clin Cancer Res. 2021;27:1681-1694.
    PubMed     Abstract available


  112. TOLANEY SM, Sahebjam S, Rhun EL, Bachelot T, et al
    Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.
    Clin Cancer Res. 2021;27:1582.
    PubMed    


    February 2021
  113. PASCUAL T, Fernandez-Martinez A, Tanioka M, Dieci MV, et al
    Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy.
    Clin Cancer Res. 2021 Feb 25. pii: 1078-0432.CCR-20-4102.
    PubMed     Abstract available


  114. SHARMA P, Abramson VG, O'Dea AP, Nye L, et al
    Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-4879.
    PubMed     Abstract available


  115. SINN BV, Loibl S, Hanusch CA, Zahm DM, et al
    Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative breast cancer.
    Clin Cancer Res. 2021 Feb 16. pii: 1078-0432.CCR-20-3113.
    PubMed     Abstract available


  116. EDLUND K, Madjar K, Lebrecht A, Aktas B, et al
    Gene expression-based prediction of neoadjuvant chemotherapy response in early breast cancer: results of the prospective multicenter EXPRESSION trial.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-2662.
    PubMed     Abstract available


  117. WANG X, Veeraraghavan J, Liu CC, Cao X, et al
    Therapeutic targeting of nemo-like kinase in primary and acquired endocrine-resistant breast cancer.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-2961.
    PubMed     Abstract available


  118. DE ANGELIS C, Fu X, Cataldo ML, Nardone A, et al
    Activation of the interferon signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer.
    Clin Cancer Res. 2021 Feb 3. pii: 1078-0432.CCR-19-4191.
    PubMed     Abstract available


  119. LIU CC, Veeraraghavan J, Tan Y, Kim JA, et al
    A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers.
    Clin Cancer Res. 2021;27:785-798.
    PubMed     Abstract available


    January 2021
  120. ANGUS L, Deger T, Jager A, Martens JWM, et al
    Detection of aneuploidy in cerebrospinal fluid from patients with breast cancer can improve diagnosis of leptomeningeal metastases.
    Clin Cancer Res. 2021 Jan 29. pii: 1078-0432.CCR-20-3954.
    PubMed     Abstract available


  121. VIDULA N, Niemierko A, Malvarosa G, Yuen M, et al
    Tumor tissue- versus plasma-based genotyping for selection of matched therapy and impact on clinical outcomes in patients with metastatic breast cancer.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-3444.
    PubMed     Abstract available


  122. PETRONI G, Buque A, Yamazaki T, Bloy N, et al
    Radiotherapy delivered before CDK4/6 inhibitors mediates superior therapeutic effects in ER+ breast cancer.
    Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-3871.
    PubMed     Abstract available


  123. ALTOE M, Kalinsky K, Marone A, Kim HK, et al
    Changes in diffuse-optical-tomography images during early stages of neoadjuvant chemotherapy correlate with tumor response in different breast cancer subtypes.
    Clin Cancer Res. 2021 Jan 15. pii: 1078-0432.CCR-20-1108.
    PubMed     Abstract available


  124. CLARK AS, Makhlin I, DeMichele A
    Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
    Clin Cancer Res. 2021;27:371-373.
    PubMed     Abstract available


  125. MA L, Gonzalez-Junca A, Zheng Y, Ouyang H, et al
    Inflammation mediates the development of aggressive breast cancer following radiotherapy.
    Clin Cancer Res. 2021 Jan 5. pii: 1078-0432.CCR-20-3215.
    PubMed     Abstract available


    December 2020
  126. COLLIN LJ, Cronin-Fenton D, Ahern TP, Goodman M, et al
    Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women.
    Clin Cancer Res. 2020 Dec 17. pii: 1078-0432.CCR-20-3974.
    PubMed     Abstract available


  127. JACOB S, Davis AA, Gerratana L, Velimirovic M, et al
    The use of serial circulating tumor DNA (ctDNA) to detect resistance alterations in progressive metastatic breast cancer.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-1566.
    PubMed     Abstract available


  128. GARRIDO-CASTRO AC, Spurr LF, Hughes ME, Li YY, et al
    Genomic characterization of de novo metastatic breast cancer.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-1720.
    PubMed     Abstract available


  129. BHATIA S, Palomares MR, Hageman L, Chen Y, et al
    A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at risk for Breast Cancer.
    Clin Cancer Res. 2020 Dec 3. pii: 1078-0432.CCR-20-3609.
    PubMed     Abstract available


    November 2020
  130. KEENAN TE, Li T, Vallius T, Guerriero JL, et al
    Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC).
    Clin Cancer Res. 2020 Nov 30. pii: 1078-0432.CCR-20-3089.
    PubMed     Abstract available


  131. SOLIMAN H, Hogue D, Han HS, Mooney B, et al
    A phase 1 trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of non-metastatic triple-negative breast cancer.
    Clin Cancer Res. 2020 Nov 20. pii: 1078-0432.CCR-20-3105.
    PubMed     Abstract available


  132. SHARMA P, Kimler BF, O'Dea AP, Nye L, et al
    Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP).
    Clin Cancer Res. 2020 Nov 18. pii: 1078-0432.CCR-20-3646.
    PubMed     Abstract available


  133. BALLINGER TJ, Jiang G, Kassem N, Radovich M, et al
    Impact of body mass index (BMI) on presence of ctDNA and disease recurrence after neoadjuvant chemotherapy for triple negative breast cancer: analysis from BRE12-158.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3341.
    PubMed     Abstract available


  134. GAO JJ, Osgood CL, Gong Y, Zhang H, et al
    FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer.
    Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3474.
    PubMed     Abstract available


  135. NARAYAN P, Prowell TM, Gao JJ, Fernandes LL, et al
    FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer.
    Clin Cancer Res. 2020 Nov 9. pii: 1078-0432.CCR-20-3652.
    PubMed     Abstract available


  136. WAHBY S, Fashoyin-Aje L, Osgood CL, Cheng J, et al
    FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third Line Treatment of Metastatic Triple-negative Breast Cancer (mTNBC).
    Clin Cancer Res. 2020 Nov 9. pii: 1078-0432.CCR-20-3119.
    PubMed     Abstract available


  137. ANDREASSEN MMS, Rodriguez-Soto AE, Conlin CC, Vidic I, et al
    Discrimination of breast cancer from healthy breast tissue using a three-component diffusion-weighted MRI model.
    Clin Cancer Res. 2020 Nov 4. pii: 1078-0432.CCR-20-2017.
    PubMed     Abstract available


  138. STENMARK TULLBERG A, Puttonen HAJ, Sjostrom M, Holmberg E, et al
    Immune infiltrate in the primary tumor predicts effect of adjuvant radiotherapy in breast cancer; results from the randomized SweBCG91RT trial.
    Clin Cancer Res. 2020 Nov 4. pii: 1078-0432.CCR-20-3299.
    PubMed     Abstract available


    October 2020
  139. COLLINS DM, Madden SF, Gaynor N, AlSultan D, et al
    Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer.
    Clin Cancer Res. 2020 Oct 29. pii: 1078-0432.CCR-20-2007.
    PubMed     Abstract available


  140. BALLHAUSEN A, Wheler JJ, Karp DD, Piha-Paul SA, et al
    Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors.
    Clin Cancer Res. 2020 Oct 28. pii: 1078-0432.CCR-20-2878.
    PubMed     Abstract available


  141. NOORDHOEK I, Treuner K, Putter H, Zhang Y, et al
    Breast Cancer Index predicts extended endocrine benefit to individualize selection of HR+ early stage breast cancer patients for 10 years of endocrine therapy.
    Clin Cancer Res. 2020 Oct 27. pii: 1078-0432.CCR-20-2737.
    PubMed     Abstract available


  142. WAHDAN-ALASWAD RS, Edgerton SM, Salem H, Kim H, et al
    Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2647.
    PubMed     Abstract available


  143. GUERINI-ROCCO E, Gray KP, Fumagalli C, Reforgiato MR, et al
    Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial.
    Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-0126.
    PubMed     Abstract available


  144. SHAH M, Wedam S, Cheng J, Fiero MH, et al
    FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Clin Cancer Res. 2020 Oct 14. pii: 1078-0432.CCR-20-2701.
    PubMed     Abstract available


  145. LEE HB, Lee SB, Kim M, Kwon S, et al
    Development and validation of a next-generation sequencing-based multigene assay to predict the prognosis of estrogen receptor-positive, HER2-negative breast cancer.
    Clin Cancer Res. 2020 Oct 7. pii: 1078-0432.CCR-20-2107.
    PubMed     Abstract available


  146. SCHROTH W, Buttner FA, Kandabarau S, Hoppe R, et al
    Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
    Clin Cancer Res. 2020 Oct 2. pii: 1078-0432.CCR-20-1923.
    PubMed     Abstract available


    September 2020
  147. BARDIA A, Modi S, Oliveira M, Cortes J, et al
    Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer.
    Clin Cancer Res. 2020 Sep 30. pii: 1078-0432.CCR-20-1068.
    PubMed     Abstract available


  148. KROP I, Abramson VG, Colleoni M, Traina TA, et al
    A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-1693.
    PubMed     Abstract available


  149. PRAT A, Tsai YH, Pascual T, Pare L, et al
    A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer.
    Clin Cancer Res. 2020 Sep 22. pii: 1078-0432.CCR-20-2793.
    PubMed     Abstract available


  150. RICHARD F, Majjaj S, Venet D, Rothe F, et al
    Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer.
    Clin Cancer Res. 2020 Sep 17. pii: 1078-0432.CCR-20-2268.
    PubMed     Abstract available


    August 2020
  151. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
    Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
    PubMed     Abstract available


    July 2020
  152. TOLANEY SM, Sahebjam S, Le Rhun E, Bachelot T, et al
    A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1764.
    PubMed     Abstract available


  153. BRAVACCINI S, Ravaioli S, Tumedei MM, Rocca A, et al
    Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter.
    Clin Cancer Res. 2020;26:3892-3893.
    PubMed    


    June 2020
  154. ESSERMAN LJ
    Personalization of Treatment is the Way Forward in Care and Trials.
    Clin Cancer Res. 2020;26:2771-2773.
    PubMed     Abstract available


    May 2020
  155. NARAYAN P, Wahby S, Gao JJ, Amiri-Kordestani L, et al
    FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
    Clin Cancer Res. 2020;26:2284-2289.
    PubMed     Abstract available


    March 2020
  156. FERNANDEZ-NOGUEIRA P, Mancino M, Fuster G, Lopez-Plana A, et al
    Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
    Clin Cancer Res. 2020;26:1432-1448.
    PubMed     Abstract available


    February 2020
  157. HUTCHINSON KE, Yost SE, Chang CW, Johnson RM, et al
    Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
    Clin Cancer Res. 2020;26:657-668.
    PubMed     Abstract available


  158. HICKS KC, Knudson KM, Lee KL, Hamilton DH, et al
    Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Clin Cancer Res. 2020;26:704-716.
    PubMed     Abstract available


  159. BUUS R, Sestak I, Barron S, Loughman T, et al
    Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
    Clin Cancer Res. 2020;26:623-631.
    PubMed     Abstract available


    January 2020
  160. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
    ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
    PubMed     Abstract available



  161. Selected Articles from This Issue.
    Clin Cancer Res. 2020;26:323.
    PubMed    


    September 2019
  162. SHEE K, Wells JD, Ung M, Hampsch RA, et al
    A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-2213.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: